Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Innate Pharma S.A. Ads (IPHA)

Innate Pharma S.A. Ads (IPHA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 420,179
  • Shares Outstanding, K 78,981
  • Annual Sales, $ 96,110 K
  • Annual Income, $ -23,250 K
  • 60-Month Beta N/A
  • Price/Sales 4.24
  • Price/Cash Flow N/A
  • Price/Book 1.84
Trade IPHA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.97 +41.56%
on 11/10/20
5.75 -2.26%
on 12/04/20
+1.75 (+45.41%)
since 11/04/20
3-Month
3.55 +58.31%
on 09/24/20
5.75 -2.26%
on 12/04/20
-0.46 (-7.55%)
since 09/04/20
52-Week
3.30 +70.30%
on 03/16/20
8.24 -31.80%
on 01/02/20
-0.53 (-8.62%)
since 12/04/19

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ: IPHA).  Such investors are advised to contact at   or...

IPHA : 5.62 (+5.64%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Las Vegas Sands, Innate Pharma, JPMorgan, and First American Financial and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Las Vegas Sands Corporation (NYSE:...

LVS : 60.11 (+2.47%)
IPHA : 5.62 (+5.64%)
JPM : 122.34 (+0.91%)
FAF : 50.05 (+2.39%)
DEADLINE ALERT for LVS, IPHA, JPM, and FAF: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

LVS : 60.11 (+2.47%)
IPHA : 5.62 (+5.64%)
JPM : 122.34 (+0.91%)
FAF : 50.05 (+2.39%)
ROSEN, A LEADING LAW FIRM, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact the Firm - IPHA

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Innate Pharma S.A. (NASDAQ: IPHA) between and , inclusive (the "Class Period"), of the important...

IPHA : 5.62 (+5.64%)
DEADLINE ALERT for EOLS, LVS, IPHA, JPM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

EOLS : 3.81 (+4.67%)
LVS : 60.11 (+2.47%)
IPHA : 5.62 (+5.64%)
JPM : 122.34 (+0.91%)
LVS, IPHA & JPM Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

LVS : 60.11 (+2.47%)
IPHA : 5.62 (+5.64%)
JPM : 122.34 (+0.91%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming December 22, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise...

IPHA : 5.62 (+5.64%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Reata Pharmaceuticals, Evolus, Las Vegas Sands, and Innate Pharma and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reata Pharmaceuticals, Inc. (NASDAQ:...

RETA : 141.15 (+1.01%)
EOLS : 3.81 (+4.67%)
LVS : 60.11 (+2.47%)
IPHA : 5.62 (+5.64%)
DEADLINE ALERT for LVS, IPHA, JPM, and FAF: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

LVS : 60.11 (+2.47%)
IPHA : 5.62 (+5.64%)
JPM : 122.34 (+0.91%)
FAF : 50.05 (+2.39%)
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

, /PRNewswire/ -- , LLP, announces that class action lawsuits have commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995...

BAMXF : 90.0250 (-0.28%)
BMWYY : 30.2200 (+1.07%)
MESO : 16.10 (+2.29%)
RCL : 82.73 (-1.98%)
LOOP : 9.30 (+9.28%)
EOLS : 3.81 (+4.67%)
IPHA : 5.62 (+5.64%)
FAF : 50.05 (+2.39%)
ZSAN : 0.6224 (+1.48%)
NVCN : 0.8644 (+4.43%)
TILE : 9.36 (+6.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies for the treatment of cancer. The company's commercial-stage product includes Lumoxiti. Innate Pharma S.A. is based in Marseille, France.

See More

Key Turning Points

2nd Resistance Point 5.93
1st Resistance Point 5.78
Last Price 5.62
1st Support Level 5.44
2nd Support Level 5.25

See More

52-Week High 8.24
Fibonacci 61.8% 6.35
Fibonacci 50% 5.77
Last Price 5.62
Fibonacci 38.2% 5.19
52-Week Low 3.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar